Navigation Links
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Date:11/6/2007

site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the international market potential for REMICADE. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in Schering-Plough's third quarter 2007 10-Q.

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation, one of the leading Japanese pharmaceutical companies, specializes in developing and marketing globally competitive pharmaceutical products in the fields of cardiovascular and metabolic diseases, brain and nerve diseases, and renal and urinary system diseases. The company, established through the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation in October 2007, drives for the expansion of its operations and the reinforcement of its future growth with the aim of becoming a global research-driven pharmaceutical company and taking on challenge of new business opportunities. Mitstubishi Tanabe Pharma Corporation is committed to protect the health of people around the world and co
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
2. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
3. Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
7. Genmab Announces 2007 First Half Year Results
8. Pharsight Achieves First License Sale for Public-Source Database
9. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Albany, New York (PRWEB) July 25, 2014 ... Transparency Market Research, "Biological Drugs Market - Global Industry ... 2020," the global biological drugs market is estimated at ... grow at a CAGR of 10.1% from 2014 to ... million in 2020. , The biological drugs market is ...
(Date:7/25/2014)... July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development and commercialization of a once-daily, oral ... gallstones, today announced financial results for the period ended ... Summary: , Reported cash and cash equivalents totaling ... at December 31, 2013.  , Reported a net ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a ... regenerative medicine, announced today that it will host ... on Tuesday, July 29, 2014, at 4:30 p.m. ... an overview of Asterias, business strategy and product ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... for the Study of ... DNA-Protein Interactions, ... launch of its Imprint(TM) Chromatin,Immunoprecipitation Kit for epigenetic research,( http://www.sigma.com/chip ... Immunoprecipitation, including columns and reagents,for DNA purification as well as ...
... April 16 Medarex, Inc.,(Nasdaq: MEDX ) ... that suggest a,potential association between higher doses of ... control and prolonged,progression-free survival in patients with relapsed ... 1/2 trial were presented at the,Annual Meeting of ...
... Masimo (Nasdaq:,MASI), the inventor of Pulse CO-Oximetry ... Atom Medical Corporation, a leading global manufacturer ... Rainbow SET Pulse,CO-Oximetry into its current and ... Masimo technology more than 10 years ago, ...
Cached Biology Technology:Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research 2Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research 3Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting 2Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting 3Atom Medical Adopts Masimo Rainbow SET Technology 2Atom Medical Adopts Masimo Rainbow SET Technology 3Atom Medical Adopts Masimo Rainbow SET Technology 4
(Date:7/25/2014)... Before the colonial era, 100,000s of people lived on ... cultures manipulated fire to control the availability of plants ... tribes continue to use fire to maintain desired habitat ... the U.S. Forest Service,s Pacific Southwest Station, will lead ... National Wildfire Refuge during the Ecological Society of America,s ...
(Date:7/25/2014)... from 25 countries and 35 states will attend ... Genetics Society of America (GSA) next week at ... will feature close to 500 presentations (including 70 ... gene expression and regulation, functional genomics, chemical biology ... a variety of diseases. , Of special ...
(Date:7/25/2014)... (SB) is a complex congenital central nervous system ... of the neural tubes during the embryonic phase. ... and fecal incontinence and neurocognitive retardation. Such problems ... of life. Researchers at Ankara Physical Medicine and ... functional performance in children with SB, using the ...
Breaking Biology News(10 mins):Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2
... of an fMRI (functional magnetic resonance imaging) technique, ... Medicine have, for the first time, visualized the ... human brain. , Their work, performed at Penn's ... of psychological stress -- which will pave the ...
... some protection to the heart from injury even if ... attack, Jefferson Medical College researchers report. , Walter Koch, ... the Department of Medicine at Jefferson Medical College of ... that the drug Darbepoietin alpha would protect the ischemic ...
... two bacteria that cause significant damage to pig and ... are now analysing the results in an attempt to ... vaccines and diagnostic kits against the bacteria. , Mycoplasma ... pig-breeding industry US$200 million each year. Mycoplasma synoviae is ...
Cached Biology News:Research Permits First-Ever Visualization of Psychological Stress in the Human Brain 2
... Savant SpeedVac Concentrators set the standard for centrifugal ... uses a combination of centrifugal force, heat and ... run., SC110A comes equipped with:, , TEFLON-coated ... , Three ...
... The first SpeedVac to have active, real-time ... SpeedVac System is the worlds first, fully ... can be stacked together to form an ... benchspace. It is also the first SpeedVac ...
... RC Standard Bio for vacuum concentrator/centrifugal ... molecular biology and biochemistry for rapid and ... systems can be expanded with pumps, different ... of rotors (eliminating sample loss by transfer), ...
... dedicated concentrator for efficient drying of small ... integrated system combines the SpeedVac™ Concentrator and ... automatic pump and rotor control, and dual ... heater time), makes the DNA120 indispensable in ...
Biology Products: